Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailAntithrombin III in the therapy of severe sepsis
Lamy, Maurice ULg; Eisele, B.

in Biomedical Progress (1996), 9

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailAntithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome : a study from the French Society of Bone Marrow Transplantation and Cellular Therapy
Duléry, Rémy; Mohty, Mohamad; Duhamel, Alain et al

in Biology of Blood & Marrow Transplantation (2014), 20

We investigated the impact of rabbit antithymocyte globulins (ATG) on patient outcomes after allogeneic stem cell transplantation (allo-SCT) for progressive myelodysplastic syndrome (MDS). Of the 242 ... [more ▼]

We investigated the impact of rabbit antithymocyte globulins (ATG) on patient outcomes after allogeneic stem cell transplantation (allo-SCT) for progressive myelodysplastic syndrome (MDS). Of the 242 consecutive patients who underwent allo-SCT for progressive MDS between October 1999 and December 2009, 93 received ATG (ATG group) at the median dose of 5 mg/kg, whereas 149 patients did not (no-ATG group). Donors were sibling (n ¼ 153) or HLA-matched unrelated (n ¼ 89). Patients received blood (n ¼ 90) or marrow (n ¼ 152) grafts after either myeloablative (n ¼ 109) or reduced-intensity (n ¼ 133) conditioning. Three-year overall and event-free survival, nonrelapse mortality, relapse, and chronic graft-versus-host disease (GVHD) development were not significantly different between the 2 groups. In contrast, acute grade II to IV GVHD occurred more often in the no-ATG group (55% of the patients) than in the ATG group (27%, P < .0001). Similar results were observed with acute grade III to IV GVHD (28% and 14% in the no-ATG group and ATG group, respectively; P ¼ .009). In multivariate analysis, after adjustment with propensity score, the absence of ATG was the strongest parameter associated with an increased risk of acute grade II to IV GVHD (hazard ratio, 2.13; 95% confidence interval, 1.35 to 3.37; P ¼.001]. ATG had no impact on overall and event-free survival or cumulative incidence of the relapse. In conclusion, the addition of ATG to allo-SCT conditioning did not increase the incidence of relapse of patients with progressive MDS. The incidence of acute GVHD was decreased without compromising outcomes. [less ▲]

Detailed reference viewed: 21 (3 ULg)
Full Text
See detailAntitrust and The challenge of policing « moligopolists »
Petit, Nicolas ULg

Conference (2015, May 29)

Detailed reference viewed: 21 (1 ULg)
Full Text
See detailAntitrust Damages in EU Law and Policy : Jurisdiction Issues and Applicable Law: Brussels I, Rome I and II
Francq, Stéphanie; Wautelet, Patrick ULg

Conference (2013, November)

This presentation (co-authored with Prof. Stéphanie Francq - UCLouvain) gives an overview of the main issues arising in relation to the private enforcement of competition law within the EU, from a private ... [more ▼]

This presentation (co-authored with Prof. Stéphanie Francq - UCLouvain) gives an overview of the main issues arising in relation to the private enforcement of competition law within the EU, from a private international law perspective. The focus is on the determination of the jurisdiction and of the applicable law [less ▲]

Detailed reference viewed: 85 (3 ULg)
Full Text
Peer Reviewed
See detailThe antitrypanosomal drug melarsoprol competitively inhibits thiamin uptake in mouse neuroblastoma cells
Szyniarowski, Piotr; Bettendorff, Lucien ULg; Schweingruber, M. E.

in Cell Biology and Toxicology (2006), 22(3), 183-187

Melarsoprol is the main drug used for the treatment of late-stage sleeping sickness, although it causes severe side-effects such as encephalopathy and polyneuropathy leading to death in some patients ... [more ▼]

Melarsoprol is the main drug used for the treatment of late-stage sleeping sickness, although it causes severe side-effects such as encephalopathy and polyneuropathy leading to death in some patients. Recent data suggest that melarsoprol and its active metabolite melarsenoxide interfere with thiamin transport and metabolism in E. coli and yeast, but there are no data concerning their possible effects on thiamin metabolism in mammalian cells. We tested both drugs on thiamin transport in cultured mouse neuroblastoma cells using C-14-labeled thiamin. Melarsoprol, competitively inhibits high-affinity thiamin transport in mouse neuroblastoma cells with a K-i of 44 mu mol/L. However, the active compound melarsenoxide has no inhibitory effect. This suggests that the side effects of melarsoprol treatment are unlikely to be due to inhibition of thiamin transport by melarsenoxide, its main metabolite in the brain. [less ▲]

Detailed reference viewed: 28 (3 ULg)
Full Text
Peer Reviewed
See detailAntitumor and anti-angiogenic effects of aplidin in the 5T33MM model, syngeneic model of multiple myeloma
Caers, Jo ULg; De Raeve, Hendrik; Lepage, Doreen et al

in British Journal of Cancer (2008), 98(12), 1966-74

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailAntitumor and radiosensitizing effects of (E)-2'-Deoxy-2'-(Fluoromethylene) cytidine, a novel inhibior of ribonucleotide diphosphate reductase on human colon carcinoma xenografts in nude mice.
Sun, Lin-Quan; Li, Ye-Xiong; Guillou, Louis et al

in Cancer Research (1997), 57

Antitumor and radiosensitizing effects of (E).2'-deoxy.2'-(fluromethyl ene) cytidine (FMdC), a novel inhibitor of ribonucleotide reductase, were evaluated on nude mice bearing s.c. xenografts and liver ... [more ▼]

Antitumor and radiosensitizing effects of (E).2'-deoxy.2'-(fluromethyl ene) cytidine (FMdC), a novel inhibitor of ribonucleotide reductase, were evaluated on nude mice bearing s.c. xenografts and liver metastases of a human colon carcinoma. FMdC given once daily or twice weekly has a dose-dependent antitumor effect. The maximum tolerated dose In the mice was reached with 10 mgi'kg applied daily over 12 days. Twice weekly administration of FMdC reduced its toxicity but lowered the antitumor effect. Treatment of preestablished liver micrometastases obtained via intrasplenic injection of tumor cells, with 5 or 10 mgfkg FMdC, signifi candy prolonged the survival of the mice as compared to controls (P < 0.025 and P < 0.001, respectively). Ten mg/kg resulted in longer survival than S mg/kg FMdC (P < 0.05). Radiotherapy alone of s.c. xenografts (10 fractions over 12 days) yielded the radiation dose required to produce local tumor control in 50% of the treated mice (TCD@O)of 43.0 Gy. When combined with FMdC, TCDsawas reduced to 22.5 and 19.0 Gy at doses of 5 and 10 mg/kg given i.p. 1 h before each irradiation, respec tively. The corresponding enhancement ratios were 1.91 and 2.43, respec lively. FMdC produced moderate and reversible myelosuppression. When 5 mg/kg FMdC was combined with irradiation, there was no increased skin or hematological toxicity as compared to radiotherapy or FMdC alone. At the 10 mg/kg level, however, lower leukocyte counts were observed. These results show that FMdC appears to be a potent anticancer drug and radiosensitizer [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailThe antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells
Hajitou, Amin; Grignet, Christine ULg; Devy, L. et al

in FASEB Journal (2002), 16

Endostatin and angiostatin are known as tumor-derived angiogenesis inhibitors, but their mechanisms of action are not yet completely defined. We report here that endostatin and angiostatin, delivered by ... [more ▼]

Endostatin and angiostatin are known as tumor-derived angiogenesis inhibitors, but their mechanisms of action are not yet completely defined. We report here that endostatin and angiostatin, delivered by adenoviral vectors, reduced in vitro the neovessel formation in the mouse aortic ring assay by 85 and 40%, respectively. We also demonstrated in vivo that both endostatin and angiostatin inhibited local invasion and tumor vascularization of transplanted murine malignant keratinocytes, and reduced by 50 and 90% the development of highly vascularized murine mammary tumors. This inhibition of tumor growth was associated with a reduction of tumor vascularization. Expression analysis of vascular endothelial growth factor (VEGF) carried out in the mouse aortic ring model revealed a 3- to 10-fold down-regulation of VEGF mRNA expression in endostatin-treated rings. A similar down-regulation of VEGF expression at both mRNA and protein levels was also observed in the two in vivo cancer models after treatment with each angiogenesis inhibitor. This suggests that endostatin and angiostatin effects may be mediated, at least in part, by their ability to down-regulate VEGF expression within the tumor. This work provides evidence that endostatin and angiostatin act on tumor cells themselves. [less ▲]

Detailed reference viewed: 82 (7 ULg)
Peer Reviewed
See detailAntitumoral Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-12-Expressing Dhd/K12 Colon Adenocarcinoma Cells
Lechanteur, Chantal ULg; Moutschen, Michel ULg; Princen, Frederic et al

in Cancer Gene Therapy (2000), 7(5), 676-82

Immunomodulating gene therapy for the treatment of malignant diseases is under extensive investigation. In this study, we induced an antitumoral immune response with murine interleukin-12 (mIL-12) and ... [more ▼]

Immunomodulating gene therapy for the treatment of malignant diseases is under extensive investigation. In this study, we induced an antitumoral immune response with murine interleukin-12 (mIL-12) and murine granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor cells in a model of peritoneal carcinomatosis. Intraperitoneal injection of DHD/K12 tumoral cells engineered to produce IL-12 or GM-CSF did not generate any tumors, whereas untransduced DHD/K12 cells gave rise to peritoneal carcinomatosis. IL-12-expressing DHD/K12 cells also protected against tumors derived from coinjected parental cells. To test whether cytokine-producing cells could elicit a memory antitumoral immune response, animals received a challenge with parental DHD/K12 cells 35 days after the injection of proliferating or irradiated DHD/K12 engineered cells. Under our experimental conditions, irradiated tumor cells did not generate any antitumoral immunity. In contrast, tumor development was delayed and survival increased in the animals vaccinated with cytokine-secreting proliferating cells. A specific cytotoxic T-lymphocyte response against DHD/K12 parental cells was observed after vaccination with GM-CSF-expressing cells. Our results demonstrated that intraperitoneal vaccination with IL-12- or GM-CSF-expressing adenocarcinoma cells induced a systemic immune antitumoral response that may be useful as an adjuvant therapy after surgical resection of colorectal cancer. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailAntiviral diabetes susceptibility gene
Geenen, Vincent ULg

in International Diabetes Monitor (2006), 18

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailAntiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002.
Fischer, A; Karasi, Jean Claude ULg; Kibibi, D et al

in HIV Medicine (2006), 7(1), 64-6

Our study aimed to complete the published data on ARV therapy in Africa by describing the baseline situation in Rwanda before the launch of a large ARV programme (ESTHER). Prescription habits, frequency ... [more ▼]

Our study aimed to complete the published data on ARV therapy in Africa by describing the baseline situation in Rwanda before the launch of a large ARV programme (ESTHER). Prescription habits, frequency and reasons for treatment interruptions but also antiviral efficay, resistance to ARVs and genotypic variability of the viruses present in Rwanda were analysed. Among the 233 patients included in the study, it appeared that a vast majority (91%) were under triple therapy and that half of them had experienced at least one treatment interruption caused mainly by drug shortage or financial difficulties. Among 60 blood samples analysed, 26 were in virological failure with a viral load above 1000 RNA copies/ml and 11 presented major drug resistance mutations. Finally, virological failure could mainly be explained by the high frequency of treatment interruptions but also by the emergence of drug resistance mutations. Consequently the major objective for the ESTHER programme to improve the situation in Rwanda will be to reduce the drug shortage and facilitate the financial accessibility of the treatments. [less ▲]

Detailed reference viewed: 9 (5 ULg)
Full Text
Peer Reviewed
See detailAntiwindup regulation of saturated linear systems
Forni, Fulvio ULg; Zaccarian, Luca; Sepulchre, Rodolphe ULg

in 51st IEEE Conference on Decision and Control (2012, December)

We consider the output regulation problem for linear systems subject to actuators saturation. A state-feedback unconstrained regulator is transformed into an error-feedback bounded regulator by ... [more ▼]

We consider the output regulation problem for linear systems subject to actuators saturation. A state-feedback unconstrained regulator is transformed into an error-feedback bounded regulator by introducing an observer which is then decomposed into the sum of "unconstrained" and "antiwindup" dynamics. The unconstrained dynamics are regulated towards a predefined reference trajectory, by a control signal u which may violate the saturation bounds during transients. The antiwindup dynamics transiently store the mismatch between unconstrained and constrained dynamics. The antiwindup design also applies to a predefined error-feedback dynamic regulator for the unconstrained system, as in standard antiwindup setting. As a particular case of distinct interest, the design provides a new global asymptotic stabilizer for saturated null-controllable systems. [less ▲]

Detailed reference viewed: 88 (21 ULg)
Full Text
Peer Reviewed
See detailAntoine Garapon, Peut-on réparer l’histoire ? Colonisation, esclavage, Shoah, Paris, Odile Jacob, 2008, 287 p.
Grandjean, Geoffrey ULg

in Cahiers de Sciences Politiques de l'ULg (2009)

This article gives a summary of a book on restorative justice.

Detailed reference viewed: 57 (5 ULg)
See detailAntoinette de Jésus
Henneau, Marie-Elisabeth ULg

in Fella, Audrey (Ed.) Les femmes mystiques. Histoire et dictionnaire (2013)

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailAnton de Kom, historiographe. La construction d’un passé national pour les esclaves du Surinam
Andringa, Kim ULg

in Amnis : Revue de Civilisation Contemporaine Europes/Amériques (2014), 13

Detailed reference viewed: 12 (0 ULg)